Evidence-based educational guide for patients and caregivers — FDA-approved uses, dosing guidelines, safety warnings, and clinical insights for muscle pain and spasm relief for US patients
Medically reviewed by U.S. Licensed Pharmacists | Last updated: July 2026
Soma 350mg (Carisoprodol) is a centrally acting skeletal muscle relaxant approved by the U.S. Food and Drug Administration (FDA) for the short-term relief of acute musculoskeletal pain and muscle spasms.[1] It is commonly prescribed for conditions such as back pain, neck pain, and other muscle injuries that cause significant discomfort. Soma is typically used as part of a comprehensive treatment plan that includes rest, physical therapy, and other supportive measures. Millions of American patients have used Soma to manage acute muscle pain effectively.
Image Size: 800×600px — Soma mechanism of action: central nervous system depression
Soma works by interrupting the communication between nerves and the brain, effectively reducing the perception of pain and relaxing tense muscles. Unlike some other muscle relaxants, Soma's exact mechanism of action is not fully understood, but it is believed to act on the central nervous system rather than directly on skeletal muscle tissue.[2]
📌 Related Guide: Learn more about Tramadol 100mg — a pain medication with a different mechanism of action.
Image Size: 800×600px — Soma FDA-approved clinical indications for US patients
Soma 350mg is indicated for the short-term treatment of acute musculoskeletal pain and muscle spasms based on FDA approval and clinical guidelines:[1][3]
Note: Results vary per individual. Soma should be used as part of a comprehensive treatment plan under medical supervision.
Image Size: 800×600px — Soma key information and specifications for US patients
| Drug Class | Centrally Acting Skeletal Muscle Relaxant |
|---|---|
| FDA-Approved Indication | Short-term (2-3 weeks) treatment of acute musculoskeletal pain and muscle spasms |
| Active Ingredient | Carisoprodol |
| Onset of Action | 30 Minutes (Oral Administration) |
| Duration of Effect | 4–6 Hours |
| Elimination Half-Life | 2.5–3 Hours (Average ~2.5 hours) |
| Available Strengths | 250mg, 350mg |
| Prescription Status | Schedule IV Controlled Substance — Prescription required in the USA |
| Common Brand Names | Soma (U.S.), Carisoprodol (generic) |
Source: FDA Label for Soma (Carisoprodol) — see references.
Image Size: 800×600px — Soma common and serious side effects
While Soma is effective for muscle pain relief, it can cause side effects. Most are dose-related and may diminish with continued therapy. Contact your healthcare provider immediately if you experience severe or persistent side effects.
Image Size: 800×600px — Soma drug interactions and contraindications
📌 Related Medication: If you are exploring other pain relief options, read our evidence-based guide on Tramadol 100mg to compare mechanisms and dosing schedules.
📘 Also See: Our comprehensive guide on Oxycodone 30mg for severe pain management.
Image Size: 800×600px — Carisoprodol pharmacology and metabolic pathways
Carisoprodol is rapidly and completely absorbed following oral administration. Peak plasma concentrations are achieved within 1 to 2 hours. The oral bioavailability of carisoprodol is approximately 80-90%, making it highly effective when taken by mouth. The drug is moderately lipophilic, allowing it to cross the blood-brain barrier effectively and exert its central nervous system effects.
Once absorbed, carisoprodol is extensively distributed throughout the body. Approximately 20-30% of the drug is bound to plasma proteins. The volume of distribution is approximately 1-2 L/kg. Its moderate lipophilicity contributes to its rapid onset of action.
Carisoprodol is extensively metabolized in the liver via the CYP450 enzyme system, primarily CYP2C19. The major metabolic pathway involves N-demethylation to form meprobamate, which is pharmacologically active and contributes significantly to the sedative and muscle relaxant effects of Soma. Meprobamate has a longer half-life than carisoprodol (approximately 10 hours), contributing to the overall duration of action.
The elimination half-life of carisoprodol ranges from 2.5 to 3 hours, with an average of approximately 2.5 hours. The half-life of its active metabolite, meprobamate, ranges from 6 to 10 hours. This short half-life profile allows for convenient dosing three to four times daily but also limits the duration of action, requiring frequent dosing for continuous symptom control.
Carisoprodol and its metabolites are primarily excreted in the urine. In patients with renal impairment, dose adjustment may be required due to reduced clearance. In patients with hepatic impairment, the metabolism of carisoprodol may be significantly reduced, necessitating dose reduction or alternative therapy.
📌 Also See: Our guide on Tramadol 100mg — a pain medication with a different pharmacological profile.
📌 Compare: Oxycodone 30mg — an opioid analgesic for more severe pain.
Images are for illustrative purposes only. This medication is available by prescription only.
📋 About This Medication
Soma 350mg (Carisoprodol) is a centrally acting skeletal muscle relaxant used for the short-term relief of acute musculoskeletal pain and muscle spasms. It works by interrupting pain signals between the nerves and the brain, providing effective muscle relaxation.
This information is for educational purposes only. Always consult your healthcare provider.
📞 Check Availability →This guide is based on evidence from the following authoritative sources. All information is reviewed and updated regularly to reflect the latest clinical guidelines and FDA recommendations.
[1] U.S. Food and Drug Administration — DailyMed: Carisoprodol (Soma) Label Information. NIH National Library of Medicine.
[2] National Institutes of Health — MedlinePlus. Carisoprodol: MedlinePlus Drug Information. NIH. Updated 2026.
[3] American Academy of Orthopaedic Surgeons. Clinical Practice Guideline for the Management of Acute Musculoskeletal Pain. 2023.
[4] National Institute of Neurological Disorders and Stroke. Musculoskeletal Pain — NINDS. NIH.
[5] U.S. Drug Enforcement Administration. Controlled Substance Schedules — Schedule IV. DEA.
Last reviewed and updated: July 14, 2026. This page is intended for educational purposes and should not replace professional medical advice.